中文 | English

Orphan drug? Another Breakthrough for“MS" - Global and China analysis. Are you ready?

Event details

DATA
Thursday September 19, 2019

VENUE
Webex

TIME
4:00 PM - 5:00 PM

RSVP
This is a FREE event
VIP tckets priority for Lingmed current clients
Please RSVP by September 18, 2019
PRESENTERS
Lingling Cao, CEO & Founder
Hank Wang, Medical advisor

REGISTER
+86 21 5386 3003

Agenda

16:00 - 16:10Linkedbio services & projects introductions    by LingLing Cao
16:10 - 16.45Orphan drug? Another Breakthrough for“MS" - Global and China analysis    by Hank Wang
16:45 - 16:55Panel discussions
16:55 - 17:00Q&A

Presenters

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany

Hank Wang
Medical advisor
Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market
Download meeting reports
©Copyright 2013 - 2019 Lingmed Limited